Kalamkas Sagandykova

Mrs. Kalamkas Sagandykova

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2024 in Medicina
Verified
Journal Article
Open access
PDF file
KSKalamkas Sagandykova
Kalamkas Sagandykova
NPNataliya Papulova
Nataliya Papulova
TATalapbek Azhenov
Talapbek Azhenov
ADAliya Darbekova
Aliya Darbekova
BABayan Aigozhina
Bayan Aigozhina
Jerome R. LechienJerome R. Lechien
Jerome R. Lechien
Chronic rhinosinusitis (CRS) is a complex inflammatory condition affecting the nasal and paranasal sinus mucosa. Gastroesophageal reflux disease (GERD) has been implicated as a potential exacerbating factor in CRS, but the specific endoscopic features of nasopharyngeal pathology in this context remain poorly understood. Background and Objectives: Chronic rhinosinusitis is a multifactorial disease with various underlying etiologies, including inflammation, anatomical factors, and environmental triggers. While gastroesophageal reflux disease has been suggested as a potential contributor to chronic rhinosinusitis, the specific endoscopic features indicative of nasopharyngeal pathology in CRS patients with GERD symptoms have not been clearly elucidated. Our aim is to identify specific endoscopic features of nasopharyngeal pathology in patients with CRS associated with GERD symptoms and to propose a method for assessing the influence of gastroesophageal reflux disease on the mucosal layer of the nose and nasopharynx. Materials and Methods: We conducted a cross-sectional observational study involving 521 adult patients presenting with symptoms suggestive of CRS. From this cohort, 95 patients with the highest scores on the Reflux Symptom Index (RSI) and Reflux Symptom Score-12 (RSS-12) questionnaires were selected as the main group. Endoscopic examinations were performed to assess the nasal and nasopharyngeal mucosa. Results: Our study revealed significant alterations in the nasopharyngeal mucosa of patients with CRS associated with GERD symptoms. Increased vascularity of the nasopharyngeal mucosa was observed in 91 patients (95.7%), while hypertrophy was noted in 83 patients (87.4%). Mucus was present in the nasopharynx of 77 patients (81.1%), exhibiting varying characteristics of color and consistency. Asymmetric hypertrophy of the oropharyngeal mucosa was noted in 62 patients (65.3%). Conclusions: We propose a method for assessing the influence of gastroesophageal reflux disease on the mucosal layer of the nose and nasopharynx, which may aid in diagnostic and management decisions. Further research is warranted to explore the potential impact of GERD symptoms on the course and severity of CRS exacerbations.

Verified
Journal Article
Open access
PDF file
KSKalamkas Sagandykova
Kalamkas Sagandykova
NPNataliya Papulova
Nataliya Papulova
GMGulmira Mukhamadiyeva
Gulmira Mukhamadiyeva
TATalapbek Azhenov
Talapbek Azhenov
Jerome R. LechienJerome R. Lechien
Jerome R. Lechien
Background: Chronic rhinosinusitis with or without nasal polyps (CRSwNPs/CRSsNPs) is an inflammatory disease that is becoming increasingly associated with laryngopharyngeal reflux disease (LPRD). Although symptom-based questionnaires, such as the Reflux Symptom Index (RSI) and Reflux Symptom Score (RSS), are widely used, there is a lack of objective endoscopic tools for assessing the nasopharyngeal and nasal manifestations of reflux. The Nasopharyngeal Reflux Endoscopic Score (NRES) is a novel endoscopic scoring system that was developed to address this issue. Objective: The objective of this study was to evaluate the diagnostic accuracy of the NRES in identifying LPRD in patients with CRS, compared with a clinical reference standard. Methods: A prospective diagnostic accuracy cohort study was conducted at two tertiary care centers in Astana, Kazakhstan, from September 2023 to February 2025. A total of 216 adults were enrolled and divided into three groups: CRS with suspected LPRD (n = 116), CRS without LPRD (n = 69), and healthy controls (n = 31). CRS was diagnosed according to the EPOS 2020 criteria. LPRD was defined using a composite reference standard comprising clinical assessment, RSS > 13, RSI, and selective 24 h pH monitoring and gastrointestinal endoscopy. All participants underwent nasopharyngeal and laryngeal endoscopy, with NRES, L-K, RFS, RSI, and RSS assessments at baseline and at 6 and 12 months. Receiver operating characteristic (ROC) analysis was used to evaluate the diagnostic performance, and Wilcoxon tests were used to analyze the changes in scores. Correlation and regression analyses were used to explore associations between scales and predictive factors. Results: At baseline, NRES scores were significantly higher in the CRS with LPRD group (mean: 11.59) than in the CRS without LPRD group (mean: 3.10) and the healthy control group (mean: 2.16) (p < 0.001). ROC analysis demonstrated excellent diagnostic accuracy, with an area under the curve (AUC) of 0.998 (95% confidence interval (CI): 0.994–1.000), a sensitivity of 98% (95% CI: 94–100%) and a specificity of 96% (95% CI: 91–99%) at an optimal cut-off point of 8.5. NRES scores showed strong correlations with RSI, RSS, and RFS scores (r > 0.76, p < 0.001). A longitudinal assessment revealed significant reductions in all scores after treatment with proton pump inhibitors and lifestyle modifications, with sustained improvement at 12 months. Regression analysis found no significant effect of age, gender, or GERD severity (LA classification) on NRES scores. Conclusions: The NRES is a highly sensitive and specific endoscopic tool for identifying nasopharyngeal changes associated with LPRD in CRS patients. It demonstrates strong correlations with established symptom-based and laryngoscopic reflux assessments and responds to anti-reflux therapy over time. The NRES may, therefore, be a valuable objective adjunct in the comprehensive evaluation and longitudinal monitoring of LPRD-associated CRS.

22 July 2026 in Medicina
Verified
Journal Article
Open access
PDF file
BABayan Aigozhina
Bayan Aigozhina
RTRais Tulebaeyv
Rais Tulebaeyv
TATalapbek Azhenov
Talapbek Azhenov
SZSerik Zhandayev
Serik Zhandayev
NPNataliya Papulova
Nataliya Papulova
KSKalamkas Sagandykova
Kalamkas Sagandykova
Background and Objectives: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a heterogeneous inflammatory disease of the nasal and paranasal sinus mucosa, associated with significant impairment in quality of life, frequent postoperative recurrence, and repeated need for systemic glucocorticosteroid therapy. Despite the availability of biologics targeting IL-4/IL-13, IL-5, and IgE, a subset of patients shows incomplete or insufficient clinical response. In this context, upstream targeting of epithelial alarmins, particularly thymic stromal lymphopoietin (TSLP), has emerged as a potential therapeutic strategy. To critically review current evidence on the role of TSLP in CRSwNP and to evaluate available data on the mechanism of action, clinical efficacy, and therapeutic potential of tezepelumab in severe and recurrent disease. Materials and Methods: A narrative review was conducted using PubMed, Scopus, and Web of Science. Studies published between 2016 and 2026 were included, comprising experimental research, phase II–III clinical trials, systematic reviews, and international guidelines. Results: TSLP functions as an epithelial alarmin that initiates and amplifies type 2 inflammation via dendritic cell activation, Th2 polarization, and activation of type 2 innate lymphoid cells (ILC2). Data suggests that tezepelumab, a monoclonal antibody targeting TSLP, may reduce inflammation and regulate the immune system. Evidence from asthma populations and relevant CRSwNP subgroups indicates potential improvements in nasal polyp score, congestion, olfactory function and quality of life. It is our understanding that the safety profile appears comparable to placebo, with no new safety concerns having been identified in long-term studies. Conclusions: Tezepelumab is a promising biologic that targets inflammation in CRSwNP. It may benefit severe, recurrent, treatment-resistant disease by modulating immune pathways. However, evidence is indirect and limited, and more trials are needed to define its efficacy, identify biomarkers, and clarify its role in treatment algorithms.

5 June 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
KSKalamkas Sagandykova
Kalamkas Sagandykova
NPNataliya Papulova
Nataliya Papulova
TATalapbek Azhenov
Talapbek Azhenov
ADAliya Darbekova
Aliya Darbekova
BABayan Aigozhina
Bayan Aigozhina
Jerome R. LechienJerome R. Lechien
Jerome R. Lechien
Chronic rhinosinusitis (CRS) is a complex inflammatory condition affecting the nasal and paranasal sinus mucosa. Gastroesophageal reflux disease (GERD) has been implicated as a potential exacerbating factor in CRS, but the specific endoscopic features of nasopharyngeal pathology in this context remain poorly understood. Background and Objectives: CRS is a multifactorial disease with various underlying etiologies, including inflammation, anatomical factors, and environmental triggers. While GERD has been suggested as a potential contributor to CRS, the specific endoscopic features indicative of nasopharyngeal pathology in CRS patients with GERD symptoms have not been clearly elucidated. Our aim is to identify specific endoscopic features of nasopharyngeal pathology in patients with CRS associated with GERD symptoms, and to propose a method for assessing the influence of GERD on the mucosal layer of the nose and nasopharynx. Materials and Methods: We conducted a cross-sectional observational study involving 521 adult patients presenting with symptoms suggestive of CRS. From this cohort, 95 patients with the highest scores on the Reflux Symptom Index (RSI) and Reflux Symptom Score-12 (RSS-12) questionnaires were selected as the main group. Endoscopic examinations were performed to assess the nasal and nasopharyngeal mucosa. Results: Our study revealed significant alterations in the nasopharyngeal mucosa of patients with CRS associated with GERD symptoms. Increased vascularity of the nasopharyngeal mucosa was observed in 91 patients (95.7%), while hypertrophy was noted in 83 patients (87.4%). Mucus was present in the nasopharynx of 77 patients (81.1%), exhibiting varying characteristics of color and consistency. Asymmetric hypertrophy of the oropharyngeal mucosa was noted in 62 patients (65.3%). Conclusions: We propose a method for assessing the influence of GERD on the mucosal layer of the nose and nasopharynx, which may aid in diagnostic and management decisions. Further research is warranted to explore the potential impact of GERD symptoms on the course and severity of CRS exacerbations.

29 November 2025 in Journal of Voice
Verified
Journal Article
Closed access
ATAliya Turayeva
Aliya Turayeva
GMGulmira Mukhamadiyeva
Gulmira Mukhamadiyeva
KSKalamkas Sagandykova
Kalamkas Sagandykova
AKAssem Kurmanova
Assem Kurmanova
SAShugyla Akhmetova
Shugyla Akhmetova
Jerome R. LechienJerome R. Lechien
Jerome R. Lechien

30 August 2026 in Наука и здравоохранение
Verified
Journal Article
Closed access
BABayan Aigozhina
Bayan Aigozhina
RTR. Tulebayev
R. Tulebayev
TAT. Azhenov
T. Azhenov
SDS. Dzhandayev
S. Dzhandayev
NPN. Papulova
N. Papulova
KSKalamkas Sagandykova
Kalamkas Sagandykova
Relevance. Chronic rhinosinusitis with nasal polyps (CRSwNP) is a severe inflammatory endotype of chronic rhinosinusitis characterised by persistent Type 2 immune activation, epithelial barrier dysfunction, tissue remodelling, and a high rate of postoperative recurrence despite advances in functional endoscopic sinus surgery (FESS) and biologic therapy. Vitamin D (25-hydroxyvitamin D, 25(OH)D) has emerged as an important immunomodulatory factor involved in sinonasal mucosal homeostasis. Aim. Analysis of current clinical, molecular, and translational data on the role of vitamin D in the pathogenesis of CRSwNP, its therapeutic potential, and its relevance for relapse prevention according to the literature. Search strategy. ublications indexed in PubMed, Scopus, Web of Science, the Cochrane Library, and eLibrary (RSCI) between 2015 and 2025 were reviewed. Fifteen key studies investigating serum 25(OH)D levels, vitamin D receptor (VDR) polymorphisms, and clinically relevant outcomes in CRSwNP were included. Results. Evidence indicates that vitamin D supports mucosal homeostasis by enhancing epithelial barrier integrity through upregulation of tight junction proteins (ZO-1, occludin), inducing antimicrobial peptides such as cathelicidin (LL-37), suppressing Type 2 inflammation, and modulating tissue remodelling pathways. Clinically, vitamin D deficiency (serum 25(OH)D <20 ng/mL) is associated with higher Lund–Mackay CT scores and an increased risk of postoperative polyp recurrence following FESS. In addition, vitamin D may enhance corticosteroid responsiveness and potentially improve the effectiveness of biologic therapy through better control of inflammatory activity. Conclusion. Vitamin D status appears to be an independent predictor of disease severity and recurrence in CRSwNP. Maintaining serum 25(OH)D levels above 30 ng/mL may contribute to epithelial barrier preservation, attenuation of Type 2 inflammation, and reduction of disease recurrence. Routine assessment of vitamin D status and targeted supplementation should be considered within perioperative management strategies for CRSwNP. Актуальность. Хронический риносинусит с полипами носа (CRSwNP) является тяжелым воспалительным эндотипом хронического риносинусита, характеризующимся стойкой иммунной активацией 2-го типа, нарушением функции эпителиального барьера, ремоделированием тканей и высокой частотой послеоперационных рецидивов, несмотря на достижения функциональной эндоскопической хирургии околоносовых пазух (FESS) и биологической терапии. Витамин D рассматривается как важный иммуномодулирующий фактор, участвующий в регуляции воспалительных процессов в слизистой оболочке полости носа и околоносовых пазух. Цель. Анализ современных клинических, молекулярных и трансляционных данных о роли витамина D в патогенезе CRSwNP, его терапевтическом потенциале и его значимости для профилактики рецидивов по данным литературы. Стратегия поиска. Проведен поиск публикаций в базах PubMed, Scopus, Web of Science, Cochrane Library и eLibrary (РИНЦ) за период 2015–2025 гг. Проанализированы 15 ключевых исследований, посвященных уровню сывороточного 25(OH)D, полиморфизмам рецептора витамина D (VDR) и клиническим исходам при CRSwNP. Результаты. Установлено, что витамин D способствует поддержанию гомеостаза слизистой оболочки за счет усиления экспрессии белков плотных контактов (ZO-1, окклюдин), индукции антимикробного пептида кателицидина (LL-37), подавления воспаления 2-го типа и регуляции процессов ремоделирования тканей. Дефицит витамина D (25(OH)D <20 нг/мл) ассоциирован с более высокими показателями по шкале Lund–Mackay и увеличением риска послеоперационного рецидива полипов после FESS до 3,5 раза. Кроме того, витамин D способен повышать чувствительность к кортикостероидам и потенциально усиливать эффективность биологической терапии. Заключение. Статус витамина D может рассматриваться как независимый предиктор тяжести заболевания и риска рецидива при CRSwNP. Поддержание уровня 25(OH)D выше 30 нг/мл может способствовать сохранению целостности эпителиального барьера, снижению выраженности воспаления 2-го типа и уменьшению частоты рецидивов. Целесообразно включение оценки уровня 25(OH)D и его коррекции в комплексное ведение пациентов с CRSwNP. Өзектілігі. Мұрын полиптері бар...